Amygdalin B17Atlas

Position A

Conventional readings take this as the compared record: Amygdalin is commonly referred to as vitamin B17 and as laetrile in commercial, alternative-health, and medical commentary.

Falsification · This account would be weakened if primary sources required the stronger intentional or unique-cause claim.

• Amygdalin is commonly referred to as vitamin B17 and as laetrile in commercial, alternative-health, and medical commentary.
• Amygdalin is sold in consumer supplement forms such as capsules and is also marketed in topical cream products.
• The U.S. Food and Drug Administration has not approved amygdalin for cancer treatment, citing safety concerns.

• Assumption (moderate): Official reviews and contemporaneous reporting are the baseline for what is settled.

Position B

Some product and advocacy materials present amygdalin or vitamin B17 as having antitumor or anticancer relevance.

Falsification · This account would be weakened if the affirming chain collapsed under primary-source scrutiny.

• Some product and advocacy materials present amygdalin or vitamin B17 as having antitumor or anticancer relevance.
• A persistent alternative narrative frames vitamin B17, laetrile, or amygdalin as the subject of a suppressed or conspiratorial cancer cure story.

• Assumption (weak): Gaps or official narrowing may hide a stronger pattern than the summary admits.